Axil Capital Partners

AIBIOS is a biotechnology company focused on developing innovative small molecules that modulate both the innate and adaptive immune systems. Their work addresses therapeutic needs in gastroenterology, respiratory, and neurological diseases. The company has created a transporter assay platform designed to detect harmful ligands that trigger immuno-inflammatory symptoms and conditions. AIBIOS also profiles natural killer cells using specific monoclonal antibodies to analyze and diagnose immune disorders. By integrating real-world data into their research approach, AIBIOS aims to provide medical professionals with effective treatments for digestive disorders stemming from gastrointestinal issues.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, focused on developing innovative therapeutic products utilizing its proprietary delivery technology. Founded in 2016, the company specializes in the ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract, eliminating the need for encapsulation. Suono Bio aims to transform the treatment of challenging diseases, particularly those involving inflammatory-mediated conditions, by enabling efficient and effective delivery of therapeutics across various tissues. This technology has the potential to enhance patient recovery from gastrointestinal diseases by ensuring that treatments reach their intended targets quickly and effectively.

TechsoMed is an Israeli medical device company focused on developing ultrasound-based real-time monitoring systems specifically for thermal ablation procedures. This technology addresses the high failure rates associated with these minimally invasive treatments, which are used in various applications, including tumor destruction, heart arrhythmia management, and blood pressure regulation. By providing real-time monitoring and control of tissue destruction, TechsoMed's system enhances the effectiveness of ablation procedures, offering significant benefits to patients, physicians, and insurance companies. The integration of their imaging and analysis unit with standard ultrasound devices allows physicians to better predict the progression of tissue destruction, thereby improving treatment outcomes in a market that has significant growth potential.

Jolly Good Inc. is a Japan-based company that specializes in developing virtual reality (VR) mobile applications tailored for the television and film industry, notably through its application GuruVR, which offers 360° content. In addition to its entertainment-focused offerings, Jolly Good also incorporates medical and digital therapy VR technology aimed at enhancing both medical and industrial applications. The company has created high-precision augmented reality (AR) and VR systems that support various initiatives, including medical training, long-term care training, and social skills development for individuals with developmental impairments. Through these innovative solutions, Jolly Good aims to improve treatment outcomes and optimize training processes for professionals in both the medical and entertainment sectors.

United Immunity, Co., Ltd., established on November 27, 2017, and headquartered in Tsu, Japan, specializes in the research, development, manufacture, and sales of pharmaceuticals, with a primary focus on cancer immunotherapy. The company is known for its innovative use of nanoparticles and lipid nanoparticles to target myeloid cells, facilitating the delivery of therapeutic agents directly to macrophages and dendritic cells. This technology supports the development of treatments for a range of conditions, including cancer, autoimmune diseases, fibrosis, and infectious diseases. United Immunity aims to advance therapeutic options and improve patient outcomes through its specialized research and development efforts.

PePerseus Proteomics is a drug discovery biotechnology venture that uses advanced antibody technology to pursue superior antibody production technology and create new medicines powerfully for people around the world who are waiting for better medical care .

LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.

Jolly Good Inc. is a Japan-based company that specializes in developing virtual reality (VR) mobile applications tailored for the television and film industry, notably through its application GuruVR, which offers 360° content. In addition to its entertainment-focused offerings, Jolly Good also incorporates medical and digital therapy VR technology aimed at enhancing both medical and industrial applications. The company has created high-precision augmented reality (AR) and VR systems that support various initiatives, including medical training, long-term care training, and social skills development for individuals with developmental impairments. Through these innovative solutions, Jolly Good aims to improve treatment outcomes and optimize training processes for professionals in both the medical and entertainment sectors.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

United Immunity, Co., Ltd., established on November 27, 2017, and headquartered in Tsu, Japan, specializes in the research, development, manufacture, and sales of pharmaceuticals, with a primary focus on cancer immunotherapy. The company is known for its innovative use of nanoparticles and lipid nanoparticles to target myeloid cells, facilitating the delivery of therapeutic agents directly to macrophages and dendritic cells. This technology supports the development of treatments for a range of conditions, including cancer, autoimmune diseases, fibrosis, and infectious diseases. United Immunity aims to advance therapeutic options and improve patient outcomes through its specialized research and development efforts.

TechsoMed is an Israeli medical device company focused on developing ultrasound-based real-time monitoring systems specifically for thermal ablation procedures. This technology addresses the high failure rates associated with these minimally invasive treatments, which are used in various applications, including tumor destruction, heart arrhythmia management, and blood pressure regulation. By providing real-time monitoring and control of tissue destruction, TechsoMed's system enhances the effectiveness of ablation procedures, offering significant benefits to patients, physicians, and insurance companies. The integration of their imaging and analysis unit with standard ultrasound devices allows physicians to better predict the progression of tissue destruction, thereby improving treatment outcomes in a market that has significant growth potential.

Himuka AM Pharma Corp. is a pharmaceutical company based in Miyazaki City, Japan, founded in February 2017. The company focuses on the research, development, and discovery of drug candidates derived from the bioactive peptide adrenomedullin (AM), which was initially discovered at the University of Miyazaki. Himuka AM Pharma aims to create derivatives of adrenomedullin that contribute to mucosal healing and clinical remission, addressing significant unmet medical needs in healthcare.